SimCell technology enables the production of genome-free bacterial cells, harnessing the advantages of whole cells for disease control while mitigating the risks associated with bacterial growth in vivo. By enzymatically shearing the bacterial genome, SimCells are rendered replication-deficient, while retaining their immunogenic cell-surface features. This unique characteristic positions SimCells as highly suitable for whole-cell bacterial vaccines. We look forward to connecting with partners to further the development of our SimCell vaccines for human or animal use.

Oxford SimCell Ltd is a spinout company from the University of Oxford dedicated to utilising SimCell technology for the development of vaccines against bacterial infections. In 2020, OSC secured a £2 million investment from angel investors to carry out Discovery activities on various vaccine pipelines. To date, we have been instrumental in progressing the E. coli pipeline to TRL5, where OSC has conducted multiple safety and immunogenicity studies in mice. As a discovery stage company, OSC currently has four vaccine candidates in the pipeline. The company core IP is based on the ‘Modified Cell’ patent (WO2021079145) exclusively licensed (worldwide) from the University of Oxford. SimCells® give us the power to use engineered microorganisms in vivo without the possibility of unwanted growth. We aim to enable new and effective ways based on SimCells to safeguard ONE health.